Phase I multicenter trial of perifosine in combination with sorafenib for patients with advanced cancers including renal cell carcinoma

@inproceedings{Schreeder2008PhaseIM,
  title={Phase I multicenter trial of perifosine in combination with sorafenib for patients with advanced cancers including renal cell carcinoma},
  author={Marshall T. Schreeder and Robert A. Figlin and Joe J. Stephenson and Luis Tob{\'i}o y Campos and Sant P. Chawla and David Robert Spigel and Alexander I. Spira and Peter Sportelli and Lesa Gardner and Robert W. Birch and Michael D. Henderson},
  year={2008}
}
16024 Background: Perifosine (PERI) is an oral alkylphosphocholine with effects on multiple pathways including Akt, MAPK and JNK. Akt is often activated in renal cell carcinoma (RCC) and associated with resistance. To evaluate the single agent activity of PERI, RCC patients (pts) were assessed in a broad phase II trial with 6/9 pts (66%) achieving clinical benefit: 3 PR's, 3 SD ≥ 6 mo's (ASCO 2007 #15622). In vitro PERI is synergistic with MAPK inhibitors. PERI + Sorafenib (SOR) may result in a… CONTINUE READING